Keith Harris, DO
Pulmonary Disease · Port Jefferson Station, NYNPI 1114026853
Payments from drug & device makers
Across 1,477 payments — averaging $577.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$434K
- GSK$195K
- Grifols USA, LLC$105K
- Verona Pharma, Inc.$103K
- Boehringer Ingelheim$10K
- Hill-rom Company, Inc$875
- plus $6K from 35 others
What the payments were for
- Consulting fees$17,2132%
- Speaking & faculty fees$704,39985%
- Travel & lodging$73,1849%
- Food & beverage$36,8684%
- Education$2280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$320,364
- Ohtuvayre$101,853
- AIRSUPRA$77,781
- Prolastin-C$54,691
- TRELEGY ELLIPTA$54,200
- Prolastin-C Liquid$48,977
- BREZTRI$3,504
- ANORO ELLIPTA$1,200
- The Vest System 205 Acute Care$875
- The Vest System Model 105 Home Care$875
- The Monarch Airway Clearance System$875
- SYMBICORT$250
- SMARTVEST$132
- Obstructive Sleep Apnea Device or Hospital Respiratory Equipment$126
- BOTOX$125
- BREZTRI AEROSPHERE$125
How this compares
$853,592 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 427 | $493,469 |
| OfevNintedanib Esylate | 19 | $380,164 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $153,230 |
| Breo ElliptaFluticasone/Vilanterol | 208 | $129,824 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 95 | $107,091 |
| Spiriva RespimatTiotropium Bromide | 102 | $99,354 |
| Dupixent PenDupilumab | 20 | $71,722 |
| Arnuity ElliptaFluticasone Furoate | 84 | $32,557 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 39 | $25,123 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $16,064 |
| Spiriva HandihalerTiotropium Bromide | 19 | $16,028 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $15,200 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 342 | $13,613 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $12,586 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $12,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $195,177 | $671,050735 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $9,837 | $517,227173 claims |
| CSL BehringZemaira | $27 | $153,23013 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $433,521 | $123,155147 claims |
| MerckDulera | $116 | $11,49915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Port Jefferson Station
- Yuval HiltzikPort Jefferson Station$282K
- Peter OttavioPort Jefferson Station$269K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.